BR112022018721A2 - Métodos de administração de uma preparação injetável de aripiprazol - Google Patents

Métodos de administração de uma preparação injetável de aripiprazol

Info

Publication number
BR112022018721A2
BR112022018721A2 BR112022018721A BR112022018721A BR112022018721A2 BR 112022018721 A2 BR112022018721 A2 BR 112022018721A2 BR 112022018721 A BR112022018721 A BR 112022018721A BR 112022018721 A BR112022018721 A BR 112022018721A BR 112022018721 A2 BR112022018721 A2 BR 112022018721A2
Authority
BR
Brazil
Prior art keywords
injectable preparation
aripiprazole
methods
administration
patient
Prior art date
Application number
BR112022018721A
Other languages
English (en)
Inventor
Harlin Matthew
Wang Xiaofeng
Wang Yanlin
Raoufinia Arash
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112022018721A2 publication Critical patent/BR112022018721A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

MÉTODOS DE ADMINISTRAÇÃO DE UMA PREPARAÇÃO INJETÁVEL DE ARIPIPRAZOL. A presente invenção refere-se aos métodos de tratamento de um paciente com esquizofrenia ou transtorno bipolar I por administração ao paciente de uma preparação injetável de aripiprazol, em que a preparação injetável é administrada ao paciente em torno de uma vez a cada dois meses.
BR112022018721A 2020-04-01 2021-04-01 Métodos de administração de uma preparação injetável de aripiprazol BR112022018721A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
PCT/JP2021/014192 WO2021201238A1 (en) 2020-04-01 2021-04-01 Methods of administering an aripiprazole injectable preparation

Publications (1)

Publication Number Publication Date
BR112022018721A2 true BR112022018721A2 (pt) 2022-11-01

Family

ID=75581573

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112022018721A BR112022018721A2 (pt) 2020-04-01 2021-04-01 Métodos de administração de uma preparação injetável de aripiprazol
BR112022018647A BR112022018647A2 (pt) 2020-04-01 2021-04-01 Métodos para dose de iniciação de tratamentos com aripipazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112022018647A BR112022018647A2 (pt) 2020-04-01 2021-04-01 Métodos para dose de iniciação de tratamentos com aripipazol

Country Status (11)

Country Link
US (3) US20230129919A1 (pt)
EP (2) EP4125903A1 (pt)
JP (2) JP2023519425A (pt)
KR (2) KR20220161403A (pt)
CN (2) CN115379842A (pt)
AU (2) AU2021248212A1 (pt)
BR (2) BR112022018721A2 (pt)
CA (3) CA3136727A1 (pt)
MX (2) MX2022012353A (pt)
TW (2) TW202200142A (pt)
WO (2) WO2021201238A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
PL1675573T4 (pl) * 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US10525057B2 (en) * 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function

Also Published As

Publication number Publication date
CA3163321C (en) 2023-12-19
JP2023520004A (ja) 2023-05-15
KR20220161402A (ko) 2022-12-06
TW202200142A (zh) 2022-01-01
TW202200141A (zh) 2022-01-01
EP3941470A1 (en) 2022-01-26
US20230129919A1 (en) 2023-04-27
US20220160621A1 (en) 2022-05-26
JP2023519425A (ja) 2023-05-10
BR112022018647A2 (pt) 2022-11-08
CA3212191A1 (en) 2021-10-07
KR20220161403A (ko) 2022-12-06
US20230225962A1 (en) 2023-07-20
MX2022012353A (es) 2022-10-31
CA3163321A1 (en) 2021-10-07
WO2021201239A1 (en) 2021-10-07
CN115379842A (zh) 2022-11-22
WO2021201238A1 (en) 2021-10-07
CN115397420A (zh) 2022-11-25
EP4125903A1 (en) 2023-02-08
MX2022012354A (es) 2022-10-31
CA3136727A1 (en) 2021-10-07
AU2021245713A1 (en) 2022-12-01
AU2021248212A1 (en) 2022-12-01

Similar Documents

Publication Publication Date Title
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
MX2022015499A (es) Metodos para tratar la enfermedad de crohn y la colitis ulcerosa.
BR112018016001A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BR112017020780A2 (pt) métodos de administração de inibidores de glutaminase
BR112022018236A2 (pt) Compostos antivirais e métodos para a sua administração
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
BR112015025424A2 (pt) tratamento de câncer usando terapias de combinação de coenzima q10
BR112018003232A2 (pt) terapias de combinação para tratamento de câncer
BR112016002574A2 (pt) composição de enzima digestiva, processo para a preparação da composição de enzima digestiva, e, método para o tratamento de um paciente adulto ou pediátrico com necessidade da composição de enzima digestiva
CO2018000196A2 (es) Agente terapéutico para tratar el síndrome de hunter y método de tratamiento
BR112018015851A2 (pt) composto, e, medicamento.
BR112014027884A2 (pt) combinações farmacêuticas para tratamento de distúrbios metabólicos
MD20150120A2 (ro) Tratamentul bolilor neurodegenerative şi miopatice de agregare proteică prin administrarea parenterală a trehalozei
BR112014011223A2 (pt) método de tratar uma doença proliferativa
BR112022018721A2 (pt) Métodos de administração de uma preparação injetável de aripiprazol
BR112019018185A2 (pt) composição para tratar uma doença de articulação humana, e, kit.
BR112014009141A2 (pt) regime de dosagem para um modulador ou agonista do receptor s1p
BR112018016721A2 (pt) uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético
BR112018073930A2 (pt) composições enterais com alto teor de proteína es-terilizada por calor contendo proteína de soro de leite que compreende micelas de proteína de soro de leite e uma fonte de caseína
BR112018016287A2 (pt) sistema de perfusão, método para administrar diretamente a um paciente em necessidade do mesmo uma dose de um fármaco antineoplásico e recipiente de perfusão
BR112022006329A2 (pt) Método de tratamento de pacientes com síndrome hepatorrenal tipo 1 e pressão arterial média baixa
BR112022018171A2 (pt) Medicamento para o tratamento e/ou a prevenção de câncer, agentes aumentando a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
Gao Wu et al. A costly lesson: fatal respiratory depression induced by clindamycin during postoperative patient controlled analgesia